173 related articles for article (PubMed ID: 8952750)
1. Studies of dehydroepiandrosterone (DHEA) as a therapeutic agent in systemic lupus erythematosus.
Van Vollenhoven RF; McGuire JL
Ann Med Interne (Paris); 1996; 147(4):290-6. PubMed ID: 8952750
[TBL] [Abstract][Full Text] [Related]
2. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial.
Chang DM; Lan JL; Lin HY; Luo SF
Arthritis Rheum; 2002 Nov; 46(11):2924-7. PubMed ID: 12428233
[TBL] [Abstract][Full Text] [Related]
3. Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus: a randomised controlled trial.
Hartkamp A; Geenen R; Godaert GL; Bijl M; Bijlsma JW; Derksen RH
Ann Rheum Dis; 2010 Jun; 69(6):1144-7. PubMed ID: 19854713
[TBL] [Abstract][Full Text] [Related]
4. Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months.
van Vollenhoven RF; Morabito LM; Engleman EG; McGuire JL
J Rheumatol; 1998 Feb; 25(2):285-9. PubMed ID: 9489820
[TBL] [Abstract][Full Text] [Related]
5. Dehydroepiandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response.
Barry NN; McGuire JL; van Vollenhoven RF
J Rheumatol; 1998 Dec; 25(12):2352-6. PubMed ID: 9858429
[TBL] [Abstract][Full Text] [Related]
6. Effects of dehydroepiandrosterone supplement on health-related quality of life in glucocorticoid treated female patients with systemic lupus erythematosus.
Nordmark G; Bengtsson C; Larsson A; Karlsson FA; Sturfelt G; Rönnblom L
Autoimmunity; 2005 Nov; 38(7):531-40. PubMed ID: 16373258
[TBL] [Abstract][Full Text] [Related]
7. Dehydroepiandrosterone suppresses interleukin 10 synthesis in women with systemic lupus erythematosus.
Chang DM; Chu SJ; Chen HC; Kuo SY; Lai JH
Ann Rheum Dis; 2004 Dec; 63(12):1623-6. PubMed ID: 15547086
[TBL] [Abstract][Full Text] [Related]
8. Hormones and lupus: defective dehydroepiandrosterone activity induces impaired interleukin-2 activity of T lymphocytes in patients with systemic lupus erythematosus.
Suzuki N; Suzuki T; Sakane T
Ann Med Interne (Paris); 1996; 147(4):248-52. PubMed ID: 8952743
[TBL] [Abstract][Full Text] [Related]
9. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
Petri MA; Lahita RG; Van Vollenhoven RF; Merrill JT; Schiff M; Ginzler EM; Strand V; Kunz A; Gorelick KJ; Schwartz KE;
Arthritis Rheum; 2002 Jul; 46(7):1820-9. PubMed ID: 12124866
[TBL] [Abstract][Full Text] [Related]
10. Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial.
van Vollenhoven RF; Engleman EG; McGuire JL
Arthritis Rheum; 1995 Dec; 38(12):1826-31. PubMed ID: 8849355
[TBL] [Abstract][Full Text] [Related]
11. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
Petri MA; Mease PJ; Merrill JT; Lahita RG; Iannini MJ; Yocum DE; Ginzler EM; Katz RS; Gluck OS; Genovese MC; Van Vollenhoven R; Kalunian KC; Manzi S; Greenwald MW; Buyon JP; Olsen NJ; Schiff MH; Kavanaugh AF; Caldwell JR; Ramsey-Goldman R; St Clair EW; Goldman AL; Egan RM; Polisson RP; Moder KG; Rothfield NF; Spencer RT; Hobbs K; Fessler BJ; Calabrese LH; Moreland LW; Cohen SB; Quarles BJ; Strand V; Gurwith M; Schwartz KE
Arthritis Rheum; 2004 Sep; 50(9):2858-68. PubMed ID: 15452837
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus.
van Vollenhoven RF; Park JL; Genovese MC; West JP; McGuire JL
Lupus; 1999; 8(3):181-7. PubMed ID: 10342710
[TBL] [Abstract][Full Text] [Related]
13. An open study of dehydroepiandrosterone in systemic lupus erythematosus.
van Vollenhoven RF; Engleman EG; McGuire JL
Arthritis Rheum; 1994 Sep; 37(9):1305-10. PubMed ID: 7945493
[TBL] [Abstract][Full Text] [Related]
14. Dehydroepiandrosterone for the treatment of systemic lupus erythematosus.
van Vollenhoven RF
Expert Opin Pharmacother; 2002 Jan; 3(1):23-31. PubMed ID: 11772330
[TBL] [Abstract][Full Text] [Related]
15. Dehydroepiandrosterone (DHEA) and systemic lupus erythematosus.
Derksen RH
Semin Arthritis Rheum; 1998 Jun; 27(6):335-47. PubMed ID: 9662752
[TBL] [Abstract][Full Text] [Related]
16. Effects of sex hormones on apoptosis in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
Liu C; Zhou H; Qu R; Liu Z
Chin Med J (Engl); 2001 Mar; 114(3):291-3. PubMed ID: 11780316
[TBL] [Abstract][Full Text] [Related]
17. [Focus on dehydroepiandrosterone (DHEA)].
Meyer P; Meier CA
Rev Med Suisse; 2005 Feb; 1(6):415-8. PubMed ID: 15786645
[TBL] [Abstract][Full Text] [Related]
18. The effect of dehydroepiandrosterone on lumbar spine bone mineral density in patients with quiescent systemic lupus erythematosus.
Hartkamp A; Geenen R; Godaert GL; Bijl M; Bijlsma JW; Derksen RH
Arthritis Rheum; 2004 Nov; 50(11):3591-5. PubMed ID: 15529389
[TBL] [Abstract][Full Text] [Related]
19. Dehydroepiandrosterone for systemic lupus erythematosus.
Crosbie D; Black C; McIntyre L; Royle PL; Thomas S
Cochrane Database Syst Rev; 2007 Oct; 2007(4):CD005114. PubMed ID: 17943841
[TBL] [Abstract][Full Text] [Related]
20. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
Fortin PR; Abrahamowicz M; Ferland D; Lacaille D; Smith CD; Zummer M;
Arthritis Rheum; 2008 Dec; 59(12):1796-804. PubMed ID: 19035431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
